Selloff or Market Correction? Either Way, Here's What to Do NextSee Overvalued Stocks

Cathie Wood's ARK ETF adjusts holdings, adds Moderna and AeroVironment stock

EditorFrank DeMatteo
Published 03/26/2024, 08:29 PM
© Reuters.
AVAV
-
MRNA
-

Cathie Wood's ARK ETFs have published their daily trades for Tuesday, March 26th, 2024, showcasing a series of strategic adjustments across various sectors. The most significant acquisition for the day was in the biotech sphere, with ARK's ARKK ETF purchasing 72,800 shares of Moderna Inc (NASDAQ:MRNA), amounting to a total dollar value of $8,035,663. This move underscores ARK's confidence in the biotech firm, known for its mRNA technology platform and COVID-19 vaccine.

Another notable transaction involved AeroVironment Inc (NASDAQ:AVAV), a company specializing in unmanned aerial vehicles. ARK's ETFs ARKQ and ARKX collectively bought 38,036 shares, reflecting a total investment of $5,786,416. This purchase follows a smaller acquisition of AeroVironment shares the previous day, indicating a growing interest in the defense and aerospace sector.

In communications, ARK continued to increase its stake in Iridium Communications Inc (NASDAQ:IRDM) by buying a total of 143,084 shares across ARKQ and ARKX ETFs, with a dollar value of $3,667,242. This follows a purchase of 90,000 shares on the previous Monday, suggesting a bullish stance on the satellite communications company.

Diving into defense, ARK's ETFs ARKQ and ARKX added 39,300 shares of Kratos Defense & Security (NASDAQ:KTOS), totaling $699,147. This investment aligns with ARK's interest in companies that are integral to national security and advanced military technology.

In a significant sell-off, ARK divested 217,799 shares of Trimble Inc (NASDAQ:TRMB) from its ARKQ and ARKX ETFs, amounting to a total value of $13,743,116. This move is part of a broader trend, as ARK has been trimming its position in the company known for GPS technology and software solutions for various industries.

Other transactions included the purchase of 73,2640 shares of Recursion Pharmaceuticals (NASDAQ:RXRX) for a value of $7,714,699 and 39,422 shares of Teradyne Inc (NASDAQ:TER), totaling $4,293,055. Additionally, ARK sold 1,770 shares of NVIDIA Corp (NASDAQ:NVDA) through its ARKG ETF, valued at $1,681,535.

The day's trades reflect ARK's ongoing strategy of investing in companies with disruptive innovation potential, while adjusting holdings to optimize the performance of its ETF portfolios. Investors following ARK's moves will likely keep a close eye on these sectors and companies as they evolve in the market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.